scholarly journals Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007

2009 ◽  
Vol 14 (12) ◽  
Author(s):  
H De Carvalho Gomes ◽  
M Muscat ◽  
D L Monnet ◽  
J Giesecke ◽  
P L Lopalco

The first pneumococcal vaccine targeting the youngest age groups, a seven-valent conjugate vaccine (PCV7), was licensed in Europe in 2001. Since then several European countries have introduced PCV7 in their childhood vaccination schedules. Still, information on vaccination schemes, vaccine uptake and impact of vaccine introduction is scarce in Europe. The following article summarises the characteristics of national pneumococcal vaccination programmes for children in 32 European countries and provides an estimate of vaccine use based on sales data for 22 countries between 2001 and 2007. There were wide variations in the recommended PCV7 vaccination schemes and in PCV7 use. High vaccine uptake was not always related to the presence of a national vaccination programme.

2006 ◽  
Vol 11 (5) ◽  
Author(s):  
M A R Bergsaker ◽  
B Feiring

Pneumococcal conjugate vaccine is being added to the routine childhood vaccination programme in Norway, after a decision by the Norwegian government.


2021 ◽  
Author(s):  
Andrea C. Carcelen ◽  
Amy K. Winter ◽  
William J. Moss ◽  
Innocent Chilumba ◽  
Irene Mutale ◽  
...  

Abstract Background: High-quality, representative serological surveys allow direct estimates of immunity profiles to inform vaccination strategies but can be costly and logistically challenging. Leveraging residual serum samples is one way to increase their feasibility.Methods: We subsampled 9,854 residual sera from a 2016 national HIV survey in Zambia and tested these specimens for anti-measles and anti-rubella virus IgG antibodies using indirect enzyme immunoassays. We demonstrate innovative methods for sampling residual sera and analyzing seroprevalence data, as well as the value of seroprevalence estimates to understand and control measles and rubella. Results: National measles and rubella seroprevalence for individuals younger than 50 years was 82·8% (95% CI 81·6, 83·9%) and 74·9% (95% CI 73·7%, 76·0%), respectively. Despite a successful childhood vaccination program, measles immunity gaps persisted across age groups and districts, indicating the need for additional activities to complement routine immunization. Prior to vaccine introduction, we estimated a rubella burden of 96 congenital rubella syndrome cases per 100,000 live births.Conclusion: Residual samples from large-scale surveys can reduce the cost and challenges of conducting serosurveys, and multiple pathogens can be tested. Procedures to access specimen quality, ensure ethical approvals, and link sociodemographic data can improve the timeliness and value of results.


2019 ◽  
Vol 220 (Supplement_4) ◽  
pp. S233-S243 ◽  
Author(s):  
Robert L Zoma ◽  
Jenny A Walldorf ◽  
Felix Tarbangdo ◽  
Jaymin C Patel ◽  
Alpha Oumar Diallo ◽  
...  

Abstract Background After successful meningococcal serogroup A conjugate vaccine (MACV) campaigns since 2010, Burkina Faso introduced MACV in March 2017 into the routine Expanded Programme for Immunization schedule at age 15–18 months, concomitantly with second-dose measles-containing vaccine (MCV2). We examined MCV2 coverage in pre- and post-MACV introduction cohorts to describe observed changes regionally and nationally. Methods A nationwide household cluster survey of children 18–41 months of age was conducted 1 year after MACV introduction. Coverage was assessed by verification of vaccination cards or recall. Two age groups were included to compare MCV2 coverage pre-MACV introduction (30–41 months) versus post-MACV introduction (18–26 months). Results In total, 15 925 households were surveyed; 7796 children were enrolled, including 3684 30–41 months of age and 3091 18–26 months of age. Vaccination documentation was observed for 86% of children. The MACV routine coverage was 58% (95% confidence interval [CI], 56%–61%) with variation by region (41%–76%). The MCV2 coverage was 62% (95% CI, 59%–65%) pre-MACV introduction and 67% (95% CI, 64%–69%) post-MACV introduction, an increase of 4.5% (95% CI, 1.3%–7.7%). Among children who received routine MACV and MCV2, 93% (95% CI, 91%–94%) received both at the same visit. Lack of caregiver awareness about the 15- to 18-month visit and vaccine unavailability were common reported barriers to vaccination. Conclusions A small yet significant increase in national MCV2 coverage was observed 1 year post-MACV introduction. The MACV/MCV2 coadministration was common. Findings will help inform strategies to strengthen second-year-of-life immunization coverage, including to address the communication and vaccine availability barriers identified.


2021 ◽  

Across the world, mass vaccination programs run by governments or third-sector organizations have saved countless lives; minimized human suffering; and maintained economic, social, and cultural functioning. Vaccination programs predominantly focus on diseases that once ravaged the infant and early childhood years. However, with significant global variation, vaccination programs also exist for adolescents, pregnant women, new parents, the elderly, and people with comorbidities as well as catch-up or booster programs for particular age groups or vaccines. Governments and organizations also run annual influenza vaccination programs for entire populations or key workers, and health-care and education workers may be subject to additional vaccination requirements. The commonality of all mass vaccination programs is that the state adopts a key role in planning, coordinating, and funding them, or implementing mechanisms to ensure vaccines’ receipt by populations. The state’s role makes mandatory vaccination a possibility. Numerous scholarship forms the evidence base for the safety, efficacy, and necessity of vaccines. However, vaccination as a practice has consistently been accompanied by a minority who doubt and refuse, either for some or all vaccines. Concern about refusal has grown in recent years. An extensive Oxford Bibliographies article, “Vaccine Hesitancy,” explains why doubt and refusal develop and persist, how scholars make sense of it, and how governments and health-care providers can address it. However, hesitancy is not the only determinant of suboptimal vaccine uptake. Vaccination programs can also fail to reach populations due to insufficient generation of demand, inefficient or inappropriate service provision, cost barriers, and access barriers. Understanding the determinants of undervaccination in any given region, country, or population group will be essential to determining what strategies, including mandatory vaccination, are appropriate. Mandatory vaccination is just one strategy among a suite of tools that governments and organizations can employ to increase uptake of vaccines by particular cohorts. Mandatory vaccination is receiving current attention due to governments in several high-income jurisdictions recently utilizing it to address parents’ vaccine hesitancy. However, as the scholarship in this article illuminates, many jurisdictions’ mandatory childhood vaccination policies predate current concerns around hesitancy. Mandates have long performed key roles in the governance of vaccination uptake, including in contexts where attention to other programmatic aspects or health promotion practices may be lacking. The author would like to acknowledge the assistance of Amy Morris in the writing of the Mandatory Vaccination of Health-Care Workers—Policies, Experiences, and Impact and the Mandatory Vaccination—Attitudinal Studies sections of this article.


2017 ◽  
Vol 46 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Li Wei Ang ◽  
Jeffery Cutter ◽  
Lyn James ◽  
Kee Tai Goh

Aims: In Singapore, pneumococcal vaccination is recommended for the elderly (i.e. those ≥65 years of age) and people with chronic medical conditions. We investigated epidemiological characteristics associated with the uptake of pneumococcal vaccine based on a nationally representative cross-sectional sample of community-living adults aged ≥50 years. Methods: The data were obtained from the National Health Surveillance Survey (NHSS) 2013. Associations between pneumococcal vaccination and sociodemographic and health-related variables were analysed using univariable and multivariable logistic regression models. Results: Among 3672 respondents aged ≥50 years in the NHSS, 7.8% had taken the pneumococcal vaccination. A higher level of education and higher monthly household income were sociodemographic characteristics independently associated with pneumococcal vaccine uptake. Health-related characteristics predictive of pneumococcal vaccine uptake were better self-rated health and having a regular family doctor/general practitioner. Among those who responded to the two questions on vaccinations, 3.9% had been vaccinated against both seasonal influenza and pneumococcal infection, while 11.1% had taken only seasonal influenza vaccination in the past year. Conclusions: There is a need to boost pneumococcal vaccination coverage among community-dwelling older adults. These findings provide insights into reviewing and tailoring public-health strategies and programmes to increase vaccine uptake in at-risk population groups.


2010 ◽  
Vol 15 (13) ◽  
Author(s):  
A Siedler ◽  
U Arndt

Routine varicella vaccination with one dose for children of 11 to 14 months was recommended in Germany in 2004 to reduce disease incidence and severe complications. A country-wide varicella sentinel surveillance system was initiated in 2005 to detect trends of disease frequency and vaccine uptake and to evaluate the vaccination programme. A convenient sample of about 1,000 paediatricians and general practitioners was recruited to report on a monthly basis on varicella cases by age groups seen in their practice, and on varicella vaccine doses administered. Sentinel data from April 2005 to March 2009 show a reduction of 55% of varicella cases in all ages; 63% in the age group 0-4 years and 38% in 5-9 year-olds. The number of vaccine doses per reporting unit in all regions and physician groups increased during the same period. The number of reported cases as well as administered vaccines differed between physician groups and regions with different reimbursement policies. Where reimbursement was settled early and vaccine doses were increasing varicella cases started to decrease early as well. Besides reimbursement policies the availability and vaccination schedules influenced vaccine uptake. Sentinel surveillance provided valid data on trends for varicella associated morbidity, vaccine uptake and the age distribution of cases. The results confirm that following the introduction of routine varicella vaccination, varicella morbidity started to decline in Germany.


Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 592-592 ◽  
Author(s):  
Mary K. Pao ◽  
Esperanza B. Papadopoulos ◽  
Nancy A. Kernan ◽  
Ann A. Jakubowski ◽  
James W. Young ◽  
...  

Abstract Despite advances in post transplant supportive care, invasive infections due to Haemophilus influenza and pneumococcus continue to result in significant morbidity and mortality long after successful HCT. Introduction of the protein-conjugated vaccines in healthy children has been associated with a reduction in invasive infections due to these organisms. Although current post transplant guidelines recommend immunization with the protein-conjugated H. flu vaccine, they still include the use of the 23-valent pure polysaccharide pneumococcal vaccine (PPV), a poor immunogen even in HLA matched sibling transplant recipients. There is limited data on the immunogenicity of any of these vaccines in recipients of an unrelated or T-cell depleted (TCD) HCT. In this study, we evaluated the responses of 270 allogeneic transplant patients who received the H flu conjugate vaccine and initial pneumococcal vaccination with either the 23-valent PPV (n=156) or a series of the protein-conjugated pneumococcal vaccine, Prevnar (n=114). The median age of the 270 patients at the time of HCT was 25.1 years (range, 0.2–69 years). Thirty-eight percent of the patients were children (<18 years of age). Donors were unrelated, HLA-mis-matched related or HLA matched related in 74, 22, and 174 cases, respectively. Seventy percent of patients underwent a TCD HCT. All vaccines were well tolerated. One child had a reversible allergic response to Prevnar. Eighty-seven percent of the patient population responded to the H flu conjugate vaccine, defined as a ≥3 fold rise in titer or seroconversion. Only 24% of patients responded to the 23-valent PPV. There was no significant difference between the response to PPV administered < or > 24 months post HCT (18% vs 28%, p=0.058), nor between children and adults (19% vs 25%, p=0.16). In contrast, 75% of patients were capable of responding to Prevnar, initiated at a median of 16 months post transplant. Response to Prevnar was significantly better in patients < 18 years of age compared to older individuals (85% vs 56%, respectively, p<0.001). There was no significant difference in the ability of children who received an unrelated or HLA matched related HCT to respond to Prevnar (85% vs 86%, p=0.385). In adults, 48% vs 69%, p=0.132) responded to Prevnar following an HLA-matched related or unrelated HCT, respect ively. Forty-one patients who failed to respond to the 23-valent PPV were subsequently immunized with a series of 3 doses of Prevnar administered 2 months apart, resulting in a 76% response rate. These data suggest that continued inclusion of the 23-valent PPV is inadequately protecting patients against a potentially preventable and often fatal disease. Consideration should be given to utilization of Prevnar in the upfront vaccination of children and adults following allogeneic HCT.


Sign in / Sign up

Export Citation Format

Share Document